Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | FURIN | P09958 | 4/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29589410 | 0.87 | NMT2 (0.39) | GLO1DPP4DPP8DPP9DPP7 | |
| SCHEMBL29590144 | 0.86 | GLO1 (0.39) | GLO1C3AR1DPP4DPP8DPP9 | |
| SCHEMBL21503894 | 0.85 | DPP4 (0.33) | GLO1DPP4DPP8DPP9DPP7 | |
| SCHEMBL30550554 | 0.81 | DPP7 (0.42) | GLO1C3AR1DPP7 | |
| SCHEMBL22927849 | 0.79 | DPP4 (0.36) | C3AR1DPP4DPP8DPP9DPP7 | |
| SCHEMBL29589433 | 0.79 | DPP4 (0.37) | GLO1DPP4DPP8DPP9DPP7 | |
| SCHEMBL16862522 | 0.78 | C3AR1 (0.46) | C3AR1DPP4DPP8DPP9DPP7 | |
| SCHEMBL28819908 | 0.78 | C3AR1 (0.46) | C3AR1DPP4DPP8DPP9DPP7 | |
| SCHEMBL6047671 | 0.78 | C3AR1 (0.46) | C3AR1DPP4DPP8DPP9DPP7 | |
| SCHEMBL29359380 | 0.78 | C3AR1 (0.46) | C3AR1DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | claimed |
| US-11957760-B2 | Folate receptor targeted nanoparticle drug conjugates and uses thereof | ELUCIDA ONCOLOGY, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4257156-A2 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-4103236-B1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| EP-4103236-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | Elucida Oncology, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220378924-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2022-12-01 | — | — | US | disclosed |
| WO-2022093793-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378924-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | GLO1 2489/4885C3AR1 1865/4885DPP4 3889/4885 |
| US-11957760-B2 | Folate receptor targeted nanoparticle drug conjugates and uses thereof | FOLR1, FOLR2, DHFR | GLO1 2489/4885C3AR1 1865/4885DPP4 3889/4885 |
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | GLO1 2489/4885C3AR1 1865/4885DPP4 3889/4885 |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | GLO1 2431/4885C3AR1 3148/4885DPP4 3437/4885 |
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | GLO1 2489/4885C3AR1 1865/4885DPP4 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.